Cargando…

Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma

Assessment of ALK gene rearrangements is strongly recommended by the Molecular Testing Guideline for Selection of Lung Cancer Patients proposed by IASLC, AMP, and CAP at the time of diagnosis for patients with advanced stage disease. Non-small-cell lung cancer (NSCLC) with ALK gene rearrangements or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagan, Carlos, Barua, Subit, Hsiao, Susan J., Mansukhani, Mahesh, Saqi, Anjali, Murty, Vundavalli, Fernandes, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2019
Materias:	Rapid Cancer Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549559/ https://www.ncbi.nlm.nih.gov/pubmed/31160357 http://dx.doi.org/10.1101/mcs.a003939

Ejemplares similares

ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing
por: Canterbury, Carleigh R., et al.
Publicado: (2021)

Key considerations for comprehensive validation of an RNA fusion NGS panel
por: Barua, Subit, et al.
Publicado: (2020)

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma
por: Hsiao, Susan J., et al.
Publicado: (2017)

Diffuse midline glioma with novel, potentially targetable, FGFR2–VPS35 fusion
por: Zanazzi, George, et al.
Publicado: (2020)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Hydrophobic profiles of the tail anchors in SLMAP dictate subcellular targeting
por: Byers, Joseph T, et al.
Publicado: (2009)

SLMAP3 isoform modulates cardiac gene expression and function
por: Mlynarova, Jana, et al.
Publicado: (2019)

Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions
por: Arias-Pulido, Hugo, et al.
Publicado: (2002)

Role of SLMAP genetic variants in susceptibility of diabetes and diabetic retinopathy in Qatari population
por: Upadhyay, Rohit, et al.
Publicado: (2015)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy
por: Smith, Stephen M., et al.
Publicado: (2022)

A case of KMT2A–SEPT9 fusion–associated acute megakaryoblastic leukemia
por: Forlenza, Christopher J., et al.
Publicado: (2018)

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021)

BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior
por: Jones, Karra A., et al.
Publicado: (2019)

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma
por: Wang, Weidong, et al.
Publicado: (2023)

SEC31A-ALK Fusion Gene in Lung Adenocarcinoma
por: Kim, Ryong Nam, et al.
Publicado: (2016)

Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
por: Parrott, Andrew M., et al.
Publicado: (2021)

Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
por: Leeman-Neill, Rebecca J., et al.
Publicado: (2020)

Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
por: Wrzeszczynski, Kazimierz O., et al.
Publicado: (2019)

Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples
por: Heymann, Jonas J., et al.
Publicado: (2014)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
por: Narayan, Gopeshwar, et al.
Publicado: (2006)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
por: Duruisseaux, Michaël, et al.
Publicado: (2016)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
por: Ma, Lin, et al.
Publicado: (2022)

Increased Expression of the Tail-Anchored Membrane Protein SLMAP in Adipose Tissue from Type 2 Tally Ho Diabetic Mice
por: Chen, Xiaoliang, et al.
Publicado: (2011)

Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome
por: Narayan, Gopeshwar, et al.
Publicado: (2003)

Characteristic promoter hypermethylation signatures in male germ cell tumors
por: Koul, Sanjay, et al.
Publicado: (2002)

Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report
por: Ning, Shangkun, et al.
Publicado: (2021)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
por: Wang, Hui Qin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3duu8bg4pp3sussq0oq0mumce0